

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application

**Listing of Claims**

1. (Currently Amended) An isolated polypeptide selected from the group consisting of:
  - (a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 19,
  - (b) a polypeptide comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 19, wherein said polypeptide has nucleic acid binding activity and
  - (c) ~~a polypeptide fragment comprising~~ an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO: 19, wherein said fragment comprises at least 30 contiguous amino acids of SEQ ID NO: 19.
2. (Previously presented) An isolated polypeptide of claim 1, having the amino acid sequence of SEQ ID NO: 19.
- 3.-7. (Cancelled)
8. (Previously presented) A method for producing a polypeptide of claim 1, the method comprising:
  - (a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a polynucleotide encoding the polypeptide of claim 1, and
  - (b) recovering the polypeptide so expressed.
- 9.-14. (Cancelled)
15. (Currently Amended) A composition comprising ~~an effective amount of a~~ polypeptide of claim 1 and a pharmaceutically acceptable excipient.

16.-27. (Cancelled)

28. (Currently Amended) A method for screening a compound for effectiveness as an agonist of the polypeptide of claim 1, said method comprising:

- (a) exposing a sample comprising the polypeptide of claim 1 to a compound; and
- (b) detecting the presence of [[any]] agonist activity of the polypeptide of claim 1 in said sample.

29. (Withdrawn) A method for screening a compound for effectiveness as an antagonist of the polypeptide of claim 1, said method comprising:

- (a) exposing a sample comprising the polypeptide of claim 1 to a compound;
- (b) detecting the presence of any antagonist activity in said sample.

30. (New) A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient, wherein administration of said compound results in the treatment or prevention of a cell proliferative disorder.